Can repeated exposure to morphine change the spinal analgesic effects of lidocaine in rats?

Journal of Research in Medical Sciences

Volumn 16, Issue 10, 2011, Pages 1361-1365

  Dabbagh, Ali ^a   Moghadam, Shervin Farkhondehkish ^a   Rajaei, Samira ^b   Mansouri, Zahra ^a   Manaheji, Homa Shardi ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Intrathecal; Lidocaine; Local anesthetic; Morphine

Indexed keywords

KETAMINE; LIDOCAINE; MORPHINE SULFATE; PLACEBO; SODIUM CHLORIDE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TOLERANCE; INDWELLING CATHETER; LONG TERM EXPOSURE; MALE; MORPHINE TOLERANCE; NONHUMAN; RAT; SPINAL ANESTHESIA; SPRAGUE DAWLEY RAT; TAIL FLICK TEST;

EID: 80955132133     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Masoumi M, Shahesmaeili A, Mirzazadeh A, Tavakoli M, Ali AZ. Opium addiction and severity of coronary artery disease: a case-control study. J Res Med Sci 2010; 15(1): 27-32.
2. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22(18): 8312-8323.
3. Liu T, Pang XY, Bai ZT, Chai ZF, Jiang F, Ji YH. Intrathecal injection of glutamate receptor antagonists/agonist selectively attenuated rat pain-related behaviors induced by the venom of scorpion Buthus martensi Karsch. Toxicon 2007; 50(8): 1073-1084.
4. White JM. Pleasure into pain: the consequences of long-term opioid use. Addict Behav 2004; 29(7): 1311-1324.
5. Ossipov MH, Lai J, King T, Vanderah TW, Malan TP, Jr., Hruby VJ, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004; 61(1): 126-148.
6. Vosoughian M, Dabbagh A, Rajaei S, Maftuh H. The duration of spinal anesthesia with 5% lidocaine in chronic opium abusers compared with nonabusers. Anesth Analg 2007; 105(2): 531-533.
7. Dabbagh A, Dahi-Taleghani M, Elyasi H, Vosoughian M, Malek B, Rajaei S, et al. Duration of spinal anesthesia with bupivacaine in chronic opium abusers undergoing lower extremity orthopedic surgery. Arch Iran Med 2007; 10(3): 316-320.
8. Kommalage M, Hoglund AU. Involvement of spinal GABA receptors in the regulation of intraspinal acetylcholine release. Eur J Pharmacol 2005; 525(1-3): 69-73.
9. Pertovaara A, Wei H. A dissociative change in the efficacy of supraspinal versus spinal morphine in the neuropathic rat. Pain 2003; 101(3): 237-250.
10. Saito Y, Kaneko M, Kirihara Y, Sakura S, Kosaka Y. Interaction of intrathecally infused morphine and lidocaine in rats (part II): effects on the development of tolerance to morphine. Anesthesiology 1998; 89(6): 1464-1470.
11. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17(6): 1031-1036.
12. Javan M, Ahmadiani A, Motamadi F, Kazemi B. Changes in G proteins genes expression in rat lumbar spinal cord support the inhibitory effect of chronic pain on the development of tolerance to morphine analgesia. Neurosci Res 2005; 53(3): 250-256.
13. Li JY, Wong CH, Huang EY, Lin YC, Chen YL, Tan PP, et al. Modulations of spinal serotonin activity affect the development of morphine tolerance. Anesth Analg 2001; 92(6): 1563-1568.
14. Akil H, Mayer DJ. Antagonism of stimulation-produced analgesia by p-CPA, a serotonin synthesis inhibitor. Brain Res 1972; 44(2): 692-697.
15. Maher CE, Eisenach JC, Pan HL, Xiao R, Childers SR. Chronic intrathecal morphine administration produces homologous mu receptor/G-protein desensitization specifically in spinal cord. Brain Res 2001; 895(1-2): 1-8.
16. Tarasiuk A, Gibbs L, Kendig JJ. Descending inhibition in neonatal rat spinal cord: actions of pentobarbital and morphine. Brain Res Bull 1996; 41(1): 39-45.
17. Reisi P, Alaei H, Babri S, Sharifi MR, Mohaddes G, Soleimannejad E, et al. Effects of treadmill running on extracellular basal levels of glutamate and GABA at dentate gyrus of streptozotocin-induced diabetic rats. J Res Med Sci 2010; 15(3): 172-174.
18. Panjehpour M, Karami-Tehrani F. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 2007; 16(12): 575-585.
19. Banafshe HR, Ghazi-Khansari M, Ejtemaei MS, Dehpour AR. Cyclosporine attenuates the adenylyl cyclase superactivation induced by chronic cannabinoid treatment. Eur J Pharmacol 2007; 557(1): 20-22.
20. Rabbani M, Tabakoff B. Chronic ethanol treatment reduces adenylyl cyclase activity in human erythroleukemia cells. Eur J Pharmacol 2001; 430(1): 19-23.
21. Kim KS, Lee KW, Lee KW, Im JY, Yoo JY, Kim SW, et al. Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci U S A 2006; 103(10): 3908-3913.
22. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005; 135(1): 247-261.
23. Li S, Lee ML, Bruchas MR, Chan GC, Storm DR, Chavkin C. Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol Pharmacol 2006; 70(5): 1742-1749.
24. Macsai M, Pataki I, Toth G, Szabo G. The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice. Regul Pept 2002; 109(1-3): 57-62.